Lauren V Huckaby1, Laura M Seese1, Gavin Hickey2, Ibrahim Sultan1, Arman Kilic1. 1. Division of Cardiac Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA. 2. Division of Cardiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Abstract
BACKGROUND: We sought to derive a risk score for 1-year mortality following orthotopic heart transplantation (OHT) in patients bridged with a contemporary centrifugal left ventricular assist device (LVAD). METHODS: Adult patients (≥18 years) in the United Network for Organ Sharing database undergoing OHT between 2010 and 2019 who were bridged with a HeartWare or HeartMate III device were included. Derivation and validation cohorts were randomly assigned with a 2:1 ratio. Threshold analysis and multivariable logistic regression were utilized to obtain adjusted odds ratios for 1-year post-OHT mortality. A risk score was generated using these adjusted odds ratios in the derivation cohort and the predictive performance of the composite index was evaluated in the validation set. RESULTS: A total of 3434 patients were identified. In the derivation cohort, the mean age was 53.5 ± 12.1 years and 1758 (76.8%) were male; 1789 (78.1%) were bridged with a HeartWare device. Multivariable logistic regression revealed that recipient age ≥50 years, bilirubin level ≥2.4 mg/dl, ischemic time ≥4 h, and preoperative hemodialysis predicted 1-year post-transplant mortality. Stratification into risk groups in the validation cohort revealed significant differences in postoperative renal failure, stroke, and short-term mortality. One-year post-transplant mortality was 5%, 6.7%, and 14.8% in the low-, moderate-, and high-risk categories, respectively (p < .001). CONCLUSIONS: Among patients bridged to OHT with newer generation centrifugal LVADs, older age, increasing bilirubin, longer ischemic time, and pre-OHT dialysis independently predicted post-transplant mortality. The composite risk score based on these factors may assist in patient selection and prognostication in those supported with contemporary LVADs.
BACKGROUND: We sought to derive a risk score for 1-year mortality following orthotopic heart transplantation (OHT) in patients bridged with a contemporary centrifugal left ventricular assist device (LVAD). METHODS: Adult patients (≥18 years) in the United Network for Organ Sharing database undergoing OHT between 2010 and 2019 who were bridged with a HeartWare or HeartMate III device were included. Derivation and validation cohorts were randomly assigned with a 2:1 ratio. Threshold analysis and multivariable logistic regression were utilized to obtain adjusted odds ratios for 1-year post-OHT mortality. A risk score was generated using these adjusted odds ratios in the derivation cohort and the predictive performance of the composite index was evaluated in the validation set. RESULTS: A total of 3434 patients were identified. In the derivation cohort, the mean age was 53.5 ± 12.1 years and 1758 (76.8%) were male; 1789 (78.1%) were bridged with a HeartWare device. Multivariable logistic regression revealed that recipient age ≥50 years, bilirubin level ≥2.4 mg/dl, ischemic time ≥4 h, and preoperative hemodialysis predicted 1-year post-transplant mortality. Stratification into risk groups in the validation cohort revealed significant differences in postoperative renal failure, stroke, and short-term mortality. One-year post-transplant mortality was 5%, 6.7%, and 14.8% in the low-, moderate-, and high-risk categories, respectively (p < .001). CONCLUSIONS: Among patients bridged to OHT with newer generation centrifugal LVADs, older age, increasing bilirubin, longer ischemic time, and pre-OHT dialysis independently predicted post-transplant mortality. The composite risk score based on these factors may assist in patient selection and prognostication in those supported with contemporary LVADs.
Authors: Tajinder P Singh; Christopher S Almond; Marc J Semigran; Gary Piercey; Kimberlee Gauvreau Journal: Circ Heart Fail Date: 2012-02-03 Impact factor: 8.790
Authors: David L Joyce; Robert E Southard; Guillermo Torre-Amione; George P Noon; Geoffrey A Land; Matthias Loebe Journal: J Heart Lung Transplant Date: 2005-09-15 Impact factor: 10.247
Authors: Omar Wever-Pinzon; Leah B Edwards; David O Taylor; Abdallah G Kfoury; Stavros G Drakos; Craig H Selzman; James C Fang; Lars H Lund; Josef Stehlik Journal: J Heart Lung Transplant Date: 2016-08-20 Impact factor: 10.247
Authors: Macarius Donneyong; Allen Cheng; Jaimin R Trivedi; Erin Schumer; Kelly C McCants; Emma J Birks; Mark S Slaughter Journal: ASAIO J Date: 2014 May-Jun Impact factor: 2.872
Authors: Nir Uriel; Ulrich P Jorde; Sang Woo Pak; Jeff Jiang; Kevin Clerkin; Hiroo Takayama; Yoshifumi Naka; P Christian Schulze; Donna M Mancini Journal: J Heart Lung Transplant Date: 2013-02 Impact factor: 10.247
Authors: Jeremiah G Allen; Arman Kilic; Eric S Weiss; George J Arnaoutakis; Timothy J George; Ashish S Shah; John V Conte Journal: Ann Thorac Surg Date: 2012-08-02 Impact factor: 4.330
Authors: Thomas C Hanff; Michael O Harhay; Stephen E Kimmel; Maria Molina; Jeremy A Mazurek; Lee R Goldberg; Edo Y Birati Journal: JAMA Cardiol Date: 2020-06-01 Impact factor: 14.676
Authors: Garrett N Coyan; Lauren V Huckaby; Carlos E Diaz-Castrillon; Alyssa M Miguelino; Arman Kilic Journal: J Card Surg Date: 2022-02-19 Impact factor: 1.620